Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC8 | Q09428 | 1/20 | 0.49 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GALR3 | O60755 | 1/20 | 0.44 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.44 |
| ▸ | GPR183 | P32249 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3913908 | 0.86 | IDO1 (0.49) | CYP11B1CYP11B2FNTAPGGT1BSMN1; SMN2 | |
| SCHEMBL3911396 | 0.84 | TP53 (0.53) | KMT2AMEN1HDAC6CYP11B1CYP11B2 | |
| SCHEMBL3111412 | 0.82 | CYP11B1 (0.51) | KMT2AMEN1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL3914923 | 0.81 | CYP11B1 (0.54) | KMT2AMEN1RAB9ACYP11B1CYP11B2 | |
| SCHEMBL3912721 | 0.80 | CYP11B1 (0.54) | CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL29541214 | 0.79 | BRD4 (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL3921773 | 0.77 | SMN1; SMN2 (0.50) | KMT2ACYP11B1CYP11B2HTTMAPK1 | |
| SCHEMBL3915564 | 0.77 | LMNA (0.45) | KMT2AMEN1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL8137118 | 0.75 | CYP11B1 (0.62) | ABCC8KCNJ11KMT2AMEN1NPC1 | |
| SCHEMBL3914606 | 0.74 | GRM2 (0.44) | RAB9ACYP11B1CYP11B2HTTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | GAUDINO JOHN | 2011-03-03 | — | — | US | disclosed |
| EP-2032538-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | Array Biopharma, Inc. (US) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007146824-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | TK1, ABL1, ROR1 | ABCC8 2920/4885KCNJ11 2639/4885KMT2A 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.